144 related articles for article (PubMed ID: 38679202)
1. Chest wall pain after single-fraction thoracic stereotactic ablative Radiotherapy: Dosimetric analysis from the iSABR trial.
Lau B; Wu YF; Cui S; Fu J; Jackson S; Pham D; Dubrowski P; Eswarappa S; Skinner L; Shirato H; Taguchi H; Gensheimer MF; Gee H; Chin AL; Diehn M; Loo BW; Moiseenko V; Vitzthum LK
Radiother Oncol; 2024 Jul; 196():110317. PubMed ID: 38679202
[TBL] [Abstract][Full Text] [Related]
2. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Manyam BV; Videtic GMM; Verdecchia K; Reddy CA; Woody NM; Stephans KL
Pract Radiat Oncol; 2019 Mar; 9(2):e187-e195. PubMed ID: 30529796
[TBL] [Abstract][Full Text] [Related]
3. Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity.
Murray L; Karakaya E; Hinsley S; Naisbitt M; Lilley J; Snee M; Clarke K; Musunuru HB; Ramasamy S; Turner R; Franks K
Br J Radiol; 2016; 89(1058):20150628. PubMed ID: 26760508
[TBL] [Abstract][Full Text] [Related]
4. Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors.
Park Y; Kim HJ; Chang AR
Radiat Oncol; 2017 Apr; 12(1):66. PubMed ID: 28381302
[TBL] [Abstract][Full Text] [Related]
5. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.
Mutter RW; Liu F; Abreu A; Yorke E; Jackson A; Rosenzweig KE
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1783-90. PubMed ID: 21868173
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer.
Bongers EM; Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
J Thorac Oncol; 2011 Dec; 6(12):2052-7. PubMed ID: 22052227
[TBL] [Abstract][Full Text] [Related]
7. Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes.
Woody NM; Videtic GM; Stephans KL; Djemil T; Kim Y; Xia P
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):427-34. PubMed ID: 22197087
[TBL] [Abstract][Full Text] [Related]
8. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
Dunlap NE; Cai J; Biedermann GB; Yang W; Benedict SH; Sheng K; Schefter TE; Kavanagh BD; Larner JM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):796-801. PubMed ID: 19427740
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Chest Wall Toxicity after Lung Stereotactic Ablative Radiotherapy.
Thibault I; Chiang A; Erler D; Yeung L; Poon I; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):28-35. PubMed ID: 26129745
[TBL] [Abstract][Full Text] [Related]
10. Chest wall dose reduction using noncoplanar volumetric modulated arc radiation therapy for lung stereotactic ablative radiation therapy.
Yu AS; Maxim PG; Loo BW; Gensheimer MF
Pract Radiat Oncol; 2018; 8(4):e199-e207. PubMed ID: 29452868
[TBL] [Abstract][Full Text] [Related]
11. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
12. Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain.
Din SU; Williams EL; Jackson A; Rosenzweig KE; Wu AJ; Foster A; Yorke ED; Rimner A
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):418-24. PubMed ID: 26254680
[TBL] [Abstract][Full Text] [Related]
13. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy.
Welsh J; Thomas J; Shah D; Allen PK; Wei X; Mitchell K; Gao S; Balter P; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):91-6. PubMed ID: 20542388
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry.
Coroller TP; Mak RH; Lewis JH; Baldini EH; Chen AB; Colson YL; Hacker FL; Hermann G; Kozono D; Mannarino E; Molodowitch C; Wee JO; Sher DJ; Killoran JH
PLoS One; 2014; 9(4):e94859. PubMed ID: 24728448
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
16. A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC.
Jumeau R; Filion É; Bahig H; Vu T; Lambert L; Roberge D; Doucet R; Campeau MP
Br J Radiol; 2017 Jul; 90(1075):20170196. PubMed ID: 28590814
[TBL] [Abstract][Full Text] [Related]
17. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT).
Stephans KL; Djemil T; Tendulkar RD; Robinson CG; Reddy CA; Videtic GM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):974-80. PubMed ID: 21300453
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Chest Wall Toxicity During Long-term Follow Up After Thoracic Stereotactic Body Radiation Therapy.
Chipko C; Ojwang J; Gharai LR; Deng X; Mukhopadhyay N; Weiss E
Pract Radiat Oncol; 2019 May; 9(3):e338-e346. PubMed ID: 30731275
[TBL] [Abstract][Full Text] [Related]
19. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer MF; Gee H; Shirato H; Taguchi H; Snyder JM; Chin AL; Vitzthum LK; Maxim PG; Wakelee HA; Neal J; Das M; Chang DT; Kidd E; Hancock SL; Shultz DB; Horst KC; Le QT; Wong S; Brown E; Nguyen N; Liang R; Loo BW; Diehn M
JAMA Oncol; 2023 Nov; 9(11):1525-1534. PubMed ID: 37707820
[TBL] [Abstract][Full Text] [Related]
20. Quantitative evaluation of correlation of dose and FDG-PET uptake value with clinical chest wall complications in patients with lung cancer treated with stereotactic body radiation therapy.
Algan O; Confer M; Algan S; Matthiesen C; Herman T; Ahmad S; Ali I
J Xray Sci Technol; 2015; 23(6):727-36. PubMed ID: 26756408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
